Adverse events associated with benznidazole treatment for Chagas disease in children and adults.

Cintia Valeria CruzAndres RabinovichGuillermo MoscatelliSamanta MoroniNicolas GonzálezGarcia-Bournissen FacundoGriselda BalleringHector FreilijFernanda Lascano

Published in: British journal of clinical pharmacology (2024)

Although 29.34% of patients experienced ADRs, most were mild to moderate, indicating a manageable safety profile for benznidazole. While optimized dosing schedules and new drugs are needed, avoiding benznidazole solely due to safety concerns is not justified.

Keyphrases

trypanosoma cruzi
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
young adults
peritoneal dialysis
patient reported outcomes